RISK WARNING: Your capital is at risk. The risks include: the lack of liquidity in this market in terms of being able to realise investments and the loss of the value of investment. When you invest any loss in value will not be covered by the Financial Services Compensation Scheme.
Please read FULL risk warning.
Ablatus Therapeutics is a MedTech company that is developing a unique tissue ablation platform - Bimodal Electric Tissue Ablation (BETA).
Investment closes only once the total pledged amount passes the minimum of £1,000,000
A pledge is not a commitment. You will be asked to confirm in the next section.
This company has not shared it's twitter feed.
Tissue ablation is a minimally invasive image-guided surgical technique, in which diseased tissue such as tumours, are killed through the delivery of energy. A needle-like probe is placed inside the target and energy applied heats and destroys the tissue. Essentially, ablation ‘cooks instead of cuts’. Currently, ablation is limited in terms of the size and location of tumours which can be treated.
BETA was originally developed within the Norfolk and Norwich University Hospital NHS Foundation Trust and spun out of the hospital as Ablatus Therapeutics in May 2016, with £495k of initial investment.
Investment Focus: Equity and Debt
About: Envestors is a FCA regulated corporate finance adviser in the UK and operates an international network of sophisticated investors investing an average of £42,000 in high growth unquoted companies seeking £250,000 to £2m in equity funding.
Contact Name: Oliver Woolley
Registered InvestorsOver 1000
Investment through platformOver £100m